• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中与 PNPLA3 的 I148M 变异及肥胖相关的循环三酰甘油特征。

Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.

机构信息

Department of Medicine, University of Helsinki, Helsinki, Finland.

出版信息

Diabetes. 2014 Jan;63(1):312-22. doi: 10.2337/db13-0774. Epub 2013 Sep 5.

DOI:10.2337/db13-0774
PMID:24009255
Abstract

We examined whether relative concentrations of circulating triacylglycerols (TAGs) between carriers compared with noncarriers of PNPLA3(I148M) gene variant display deficiency of TAGs, which accumulate in the liver because of defective lipase activity. We also analyzed the effects of obesity-associated nonalcoholic fatty liver disease (NAFLD) independent of genotype, and of NAFLD due to either PNPLA3(I148M) gene variant or obesity on circulating TAGs. A total of 372 subjects were divided into groups based on PNPLA3 genotype or obesity. Absolute and relative deficiency of distinct circulating TAGs was observed in the PNPLA3(148MM/148MI) compared with the PNPLA3(148II) group. Obese and 'nonobese' groups had similar PNPLA3 genotypes, but the obese subjects were insulin-resistant. Liver fat was similarly increased in obese and PNPLA3(148MM/148MI) groups. Relative concentrations of TAGs in the obese subjects versus nonobese displayed multiple changes. These closely resembled those between obese subjects with NAFLD but without PNPLA3(I148M) versus those with the I148M variant and NAFLD. The etiology of NAFLD influences circulating TAG profiles. 'PNPLA3 NAFLD' is associated with a relative deficiency of TAGs, supporting the idea that the I148M variant impedes intrahepatocellular lipolysis rather than stimulates TAG synthesis. 'Obese NAFLD' is associated with multiple changes in TAGs, which can be attributed to obesity/insulin resistance rather than increased liver fat content per se.

摘要

我们研究了携带与不携带 PNPLA3(I148M) 基因突变的个体之间循环三酰甘油(TAGs)的相对浓度是否存在缺陷,因为这种缺陷会导致脂肪酶活性缺陷,从而使肝脏内的 TAGs 堆积。我们还分析了非酒精性脂肪性肝病 (NAFLD) 与基因型无关的肥胖相关性,以及由于 PNPLA3(I148M) 基因突变或肥胖引起的 NAFLD 对循环 TAGs 的影响。共有 372 名受试者根据 PNPLA3 基因型或肥胖情况分组。与 PNPLA3(148II) 组相比,PNPLA3(148MM/148MI) 组存在明显的循环 TAGs 绝对和相对缺乏。肥胖组和“非肥胖”组具有相似的 PNPLA3 基因型,但肥胖组存在胰岛素抵抗。肥胖组和 PNPLA3(148MM/148MI) 组的肝脂肪含量均增加。肥胖组与非肥胖组相比,TAGs 的相对浓度发生了多种变化。这些变化与非酒精性脂肪性肝病但不携带 PNPLA3(I148M) 与携带 I148M 变异体和非酒精性脂肪性肝病的患者相比,肥胖患者的变化非常相似。NAFLD 的病因会影响循环 TAG 谱。“PNPLA3 NAFLD”与 TAG 相对缺乏有关,这支持了 I148M 变体阻碍肝细胞内脂肪分解而不是刺激 TAG 合成的观点。“肥胖性 NAFLD”与 TAG 的多种变化有关,这可能归因于肥胖/胰岛素抵抗,而不是肝脏脂肪含量本身的增加。

相似文献

1
Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.非酒精性脂肪性肝病中与 PNPLA3 的 I148M 变异及肥胖相关的循环三酰甘油特征。
Diabetes. 2014 Jan;63(1):312-22. doi: 10.2337/db13-0774. Epub 2013 Sep 5.
2
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.循环三酰甘油特征与 TM6SF2 中的 E167K 变异相关的非酒精性脂肪性肝病患者的胰岛素敏感性。
J Hepatol. 2015 Mar;62(3):657-63. doi: 10.1016/j.jhep.2014.10.010. Epub 2014 Oct 19.
3
Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3.脂肪组织在非酒精性脂肪性肝病中由于肥胖而发生炎症,但在非酒精性脂肪性肝病中由于 PNPLA3 的遗传变异则不会发生炎症。
Diabetologia. 2013 Apr;56(4):886-92. doi: 10.1007/s00125-013-2829-9. Epub 2013 Jan 19.
4
Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.肝脂肪变性和PNPLA3 I148M变异与血清胎球蛋白-A相关,且独立于胰岛素抵抗。
Eur J Clin Invest. 2014 Jul;44(7):627-33. doi: 10.1111/eci.12280.
5
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.载脂蛋白基因 PNPLA3 I148M 多态性与血糖正常人群的胰岛素抵抗和非酒精性脂肪性肝病相关。
Liver Int. 2011 Oct;31(9):1326-31. doi: 10.1111/j.1478-3231.2011.02526.x. Epub 2011 Apr 5.
6
The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.I148M PNPLA3 多态性影响脂肪肝患者和健康对照者的血清脂联素。
BMC Gastroenterol. 2012 Aug 16;12:111. doi: 10.1186/1471-230X-12-111.
7
Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation.I148M PNPLA3 携带者中脂肪肝与胰岛素抵抗的分离:二酰基甘油 (DAG) FA18:1 脂质种类的差异可能是一个解释。
Nutrients. 2018 Sep 17;10(9):1314. doi: 10.3390/nu10091314.
8
I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.PNPLA3基因中的I148M变异体可降低中心性肥胖和代谢疾病风险,但会增加非酒精性脂肪性肝病的患病几率。
Liver Int. 2015 Dec;35(12):2537-46. doi: 10.1111/liv.12909. Epub 2015 Jul 23.
9
PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.非酒精性脂肪性肝病、肥胖症和糖尿病前期患者的 PNPLA3 I148M 多态性。
J Gastrointestin Liver Dis. 2019 Dec 9;28(4):433-438. doi: 10.15403/jgld-506.
10
A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.载脂蛋白 C3 基因变异与肥胖人群非酒精性脂肪性肝病的组织学参数无关,但载脂蛋白 PLA3 基因变异与之相关。
Obesity (Silver Spring). 2013 Oct;21(10):2138-45. doi: 10.1002/oby.20366. Epub 2013 Jun 6.

引用本文的文献

1
Polymorphism Is Inversely Correlated with Aortic Stiffness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Without Fibrosis.多态性与无纤维化的代谢功能障碍相关脂肪性肝病患者的主动脉僵硬度呈负相关。
Int J Mol Sci. 2025 Apr 1;26(7):3256. doi: 10.3390/ijms26073256.
2
Post-hoc analysis of the tofogliflozin post-marketing surveillance study (J-STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI.托格列净上市后监测研究(J-STEP/LT)的事后分析:无论体重指数如何,托格列净均可改善2型糖尿病患者的肝功能。
J Diabetes Investig. 2025 Apr;16(4):615-628. doi: 10.1111/jdi.14402. Epub 2025 Jan 17.
3
Metabolomics at the cutting edge of risk prediction of MASLD.
代谢组学处于非酒精性脂肪性肝病(MASLD)风险预测的前沿。
Cell Rep Med. 2024 Dec 17;5(12):101853. doi: 10.1016/j.xcrm.2024.101853. Epub 2024 Dec 9.
4
The association between platelet-related parameters and nonalcoholic fatty liver disease in a metabolically healthy nonobese population.血小板相关参数与代谢健康非肥胖人群中非酒精性脂肪肝的相关性。
Sci Rep. 2024 Mar 13;14(1):6118. doi: 10.1038/s41598-024-56796-7.
5
PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content.PNPLA3 rs738409 风险基因型使 TyG 指数与 HOMA2-IR 和肝内脂质含量脱钩。
Cardiovasc Diabetol. 2023 Mar 21;22(1):64. doi: 10.1186/s12933-023-01792-w.
6
The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases.非酒精性脂肪性肝病与心血管疾病之间的遗传相互作用。
Front Genet. 2022 Aug 10;13:971484. doi: 10.3389/fgene.2022.971484. eCollection 2022.
7
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.非酒精性脂肪性肝病的代谢组学和脂质组学:生物标志物和非侵入性诊断检测。
Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856. doi: 10.1038/s41575-021-00502-9. Epub 2021 Sep 10.
8
Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.使用人诱导多能干细胞建立与 PNPLA3 相关的非酒精性脂肪性肝病模型。
Hepatology. 2021 Dec;74(6):2998-3017. doi: 10.1002/hep.32063. Epub 2021 Sep 27.
9
Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology.全基因组关联研究血清肝酶提示多种代谢和肝脏病理。
Nat Commun. 2021 Feb 5;12(1):816. doi: 10.1038/s41467-020-20870-1.
10
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.综述文章:遗传学在非酒精性脂肪性肝炎患者精准医学中的新兴作用。
Aliment Pharmacol Ther. 2020 Jun;51(12):1305-1320. doi: 10.1111/apt.15738. Epub 2020 May 7.